Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Kirsty on +44 1494 818057 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Kirsty Morris
Senior Account Manager
+44 1494 818057

Zenopa, you have done it again! By 'it' I mean you have supported my application to a great company where so far, I feel like I fit right in.
Natasha, 2013

Sandoz begins phase III trial of biosimilar etanercept

24 June 2013 17:30 in Consumer Healthcare News

Sandoz has announced the launch of a phase III trial of its new biosimilar etanercept, for the treatment of moderate to severe chronic plaque-type psoriasis.

This therapy is a biosimilar version of Enbrel, a tumour necrosis factor alpha inhibitor from Amgen that is approved for the treatment of rheumatoid arthritis, psoriasis and other conditions.

Sandoz's clinical programme was developed in consultation with regulatory authorities in the US and EU, with results from the study expected to support regulatory submissions in both territories.

Extensive preclinical and clinical data has demonstrated that the Sandoz biosimilar is highly similar to Enbrel, thereby justifying the progression to phase III testing.

Dr Mark McCamish, the company's head of global biopharmaceutical development, said: "Sandoz remains steadfast in its commitment to significantly increase worldwide access to essential, high-quality and life-enhancing biopharmaceuticals."

The firm's portfolio of around 1,100 medicines is currently available to more than 90 percent of the world's population.ADNFCR-8000103-ID-801603369-ADNFCR

Other news stories from 24/06/2013

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd